Here are the 8-K filings from Iovance Biotherapeutics, Inc. (IOVA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow IOVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IOVA filings page.
Iovance Biotherapeutics, Inc. updated its corporate presentation, which reports full-year 2026 revenue guidance raised to $410 million–$420 million from $350 million–$370 million; the midpoint is $55 million, or ~15%, above the prior range. Third-quarter 2026 revenue was ~$122 million, with ~80% year-over-year and ~22% quarter-over-quarter growth. Cash position was ~$382 million as of September 30, 2026, comprising cash, cash equivalents, short-term investments and restricted cash; the presentation describes a cash runway well into 2029. Margin from cost of sales was ~60% in Q3 and 54% year to date, excluding depreciation and amortization.
Lifileucel is in the ongoing Phase 3 TILVANCE-301 trial for frontline advanced melanoma, comparing lifileucel plus pembrolizumab with pembrolizumab alone. Interim data as of October 14, 2026, including partial independent review committee data, reported a 24.6% objective response rate (17/69) in the non-squamous NSCLC KRAS prior-treatment sensitivity population and 59.1% (13/22) in a KRAS-wild-type, HER2-wild-type, ever-smoker subgroup. Planned supplemental BLA submissions are listed for NSCLC cohorts in 2027 and 2028, and soft-tissue sarcoma cohorts in 2028–2029.
Iovance Biotherapeutics reported third-quarter 2026 total revenue of $121.469 million, compared with $67.455 million in the third quarter of 2025; the company described year-over-year growth as approximately 80%. U.S. Amtagvi revenue increased approximately 77%, and gross margin increased to approximately 60%. Net loss was $22.271 million, versus $91.253 million a year earlier. Iovance said it remains on track for full-year 2026 total revenue of $410 million to $420 million.
In clinical updates, Iovance reported a 24.6% objective response rate among 69 patients with non-squamous metastatic non-small-cell lung cancer and a 59.1% rate in a biomarker-selected subgroup; the POSITILITY trial is underway. The company reported a confirmed 55.6% response rate among 9 patients with UPS and DDLPS, with the SARATOGA registrational trial underway. Iovance is completing enrollment in Cohorts 1 and 2 of IOV-LUN-202 and preparing for a supplemental Biologics License Application submission. More than 1,000 patients have been commercially treated with Amtagvi.
Iovance Biotherapeutics, Inc. reported updated Phase 2 IOV-LUN-202 results: 17 of 69 patients with previously treated non-squamous metastatic non-small-cell lung cancer responded, an objective response rate of 24.6% as of October 14, 2026. A retrospective subgroup defined by KRAS wild-type, HER2 wild-type and current or former smoking had 13 responses among 22 patients, an objective response rate of 59.1%. Fifteen responses were confirmed and two were unconfirmed partial responses awaiting confirmation; independent radiologic assessments are ongoing.
POSITILITY will prospectively evaluate the biomarker-enriched approach, with enrollment planned to begin in November 2026 and a potential registrational pathway subject to FDA feedback. Cohorts 1 and 2 are completing enrollment, and an sBLA for lifileucel in non-squamous mNSCLC is planned for 2027. Lifileucel remains investigational for mNSCLC.
Iovance Biotherapeutics updated its corporate presentation for healthcare conferences, analysts and stockholders, covering its commercial business, financial outlook and TIL pipeline. It reported approximately $99 million in second-quarter 2026 revenue, more than 10% above guidance, and approximately 66% year-over-year growth. Full-year 2026 revenue guidance is $410 million to $420 million, with a midpoint $55 million, or approximately 15%, above the prior $350 million to $370 million range.
Its cash position, defined as cash, cash equivalents, short-term investments and restricted cash, was approximately $304 million as of June 30, 2026, with runway into the second half of 2028. Iovance reported a 56% margin from cost of sales in 2Q26, excluding depreciation and amortization, and 50% year to date. It lists approximately 100 authorized treatment centers as of October 5, 2026, and annual manufacturing capacity above 5,000 patients across North America, Europe and APAC.
In nonsquamous metastatic non-small cell lung cancer, interim data showed a 25.6% objective response rate among 39 patients; median duration of response was not reached at a median follow-up of 25.4 months. The presentation also outlines a Phase 3 frontline melanoma trial and Phase 2 registrational studies in lung cancer and soft-tissue sarcoma.
Iovance Biotherapeutics (IOVA) raised its full-year 2026 total revenue guidance to $410 million to $420 million, citing strong U.S. demand for Amtagvi and Proleukin. The midpoint increase is $55 million, or ~15%, over the previous guidance range of $350 million to $370 million; the new range implies nearly 60% annual total revenue growth.
Iovance reported record second-quarter 2026 total product revenue of $99.3 million. Its authorized treatment center (ATC) network has grown to approximately 100 centers and remains on track to reach at least 110 by year-end 2026. Management said increasing patient demand and its current manufacturing schedule provide strong visibility into third- and fourth-quarter revenue. Lifileucel continues to advance across registrational programs in new solid tumor indications, while the company cited manufacturing and operating efficiencies as accelerating progress toward profitability. Iovance describes Amtagvi as the first FDA-approved one-time treatment for previously treated advanced melanoma; it is approved in three global markets. The company expects to report third-quarter 2026 results in early November 2026.
Iovance Biotherapeutics, Inc. updated its corporate presentation on August 6, 2026. The materials are used for presentations at healthcare conferences and in meetings with analysts, existing stockholders, and other interested parties.
The updated presentation is provided as Exhibit 99.1 and is incorporated by reference, making its contents part of the company’s public disclosures.
Iovance Biotherapeutics reported record second-quarter 2026 revenue of $99.3 million, up 66% year over year, with roughly $91 million from Amtagvi and gross margin of 56%. Operating loss narrowed to $51.9 million and net loss to $47.3 million, while six-month net loss improved to $126.4 million from $227.8 million.
Management is reviewing its prior 2026 revenue guidance of $350–$370 million and plans to update it in the third quarter. The cash position, including cash, cash equivalents, short-term investments and restricted cash, was about $304 million as of June 30, 2026, which the company expects will fund operations into the second half of 2028.
The update also highlights progress across the TIL pipeline: Fast Track Designation for lifileucel in soft tissue sarcomas, advancing registrational programs in metastatic non-squamous NSCLC and advanced melanoma, next-generation gene-edited and IL-12 tethered TIL therapies, and expanding global Amtagvi access with recent approval in Australia and ongoing reviews in the UK and Switzerland.
Iovance Biotherapeutics, Inc. updated its corporate presentation used for investor and conference meetings, outlining commercial progress, pipeline data, and financial guidance. The company highlights Amtagvi as the first FDA-approved one-time T cell therapy for solid tumors in second-line and later advanced melanoma, with more than 1,500 patients treated across commercial and clinical use.
The presentation reiterates Q2 2026 revenue guidance of $86M–$88M and full-year 2026 revenue guidance of $350M–$370M, supported by cash of about $319M as of March 31, 2026 and stated cash runway into 2028. Iovance reports over 90 authorized treatment centers, more than 200 million covered patient lives, and broad payer coverage generally aligned with clinical data and guidelines.
Clinical data summaries emphasize deep and durable responses in advanced melanoma, early but encouraging results in nonsquamous non-small cell lung cancer and soft tissue sarcomas, and proof-of-concept efforts in endometrial cancer. The company also details next-generation TIL and IL-2/IL-12-based programs intended to enhance efficacy and durability in solid tumors.
Iovance Biotherapeutics reported that stockholders approved all seven proposals at its Annual Meeting, including an amendment to the 2020 Employee Stock Purchase Plan adding 1,000,000 shares and an increase in authorized common stock from 500,000,000 to 650,000,000 shares. Directors were re-elected, executive compensation received advisory approval, and Ernst & Young LLP was ratified as auditor.
The company also received marketing authorization from Australia’s Therapeutic Goods Administration for Amtagvi (lifileucel) to treat previously treated advanced melanoma. Amtagvi is described as the first T cell therapy for a solid tumor cancer and the first option in Australia for advanced melanoma after anti-PD-1 and targeted therapy.
Iovance Biotherapeutics reported first quarter 2026 revenue of about $71.4 million, approximately 45% higher than a year earlier, reflecting strong demand for Amtagvi. The company issued revenue guidance of $86–88 million for the second quarter and $350–370 million for full-year 2026, signaling expectations for continued growth.
Iovance remains unprofitable, with a net loss of $79.0 million and a loss per share of $0.19, though both improved versus 2025. Management highlighted internal manufacturing efficiencies, cost reductions, and a 40% confirmed objective response rate in metastatic serous endometrial cancer as it advances multiple TIL therapy trials. Cash, cash equivalents, and investments totaled $313.4 million as of March 31, 2026.
Iovance Biotherapeutics, Inc. reported that board member Wendy Yarno has notified the Board she will retire and will not stand for re-election at the company’s annual meeting of stockholders, which is anticipated to be held in June 2026.
Ms. Yarno will continue to serve as a director until the annual meeting. The company stated that her decision to retire is not due to any disagreement with Iovance regarding its operations, policies, or practices, and publicly thanked her for her service on the Board.
Iovance Biotherapeutics reported strong topline growth for the fourth quarter and full year 2025 while remaining loss-making as it scales commercialization of Amtagvi. Fourth-quarter product revenue reached $86.8M, up from $73.7M a year earlier, contributing to full-year 2025 revenue of $263.5M versus $164.1M in 2024, meeting its $250M–$300M guidance range. Q4 gross margin improved to 50%, but total 2025 costs and expenses of $666.9M led to a net loss of $391.0M, or $(1.09) per share. Cash, cash equivalents and investments were $297.0M as of December 31, 2025, with an investor presentation indicating total cash of about $303M and runway into Q3 2027. Strategically, growth is driven by increasing Amtagvi demand in advanced melanoma, while the pipeline advanced with a U.S. FDA Fast Track designation for lifileucel in second-line advanced non-small cell lung cancer and multiple ongoing registrational and proof-of-concept trials in solid tumors.
Iovance Biotherapeutics, Inc. filed a report describing an updated corporate presentation it will use with healthcare conference audiences, analysts, current stockholders, and others. In that presentation, the company states it expects to achieve its previously disclosed full-year 2025 revenue guidance range of $250 to $300 million in the first full calendar year of sales for its therapy Amtagvi. The updated slide deck is provided as Exhibit 99.1 to the report.
Iovance Biotherapeutics filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025 and recent updates. The press release is included as Exhibit 99.1.
The information under Item 2.02 is furnished and not deemed “filed” under Section 18 of the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL.
Iovance Biotherapeutics, Inc. (IOVA) submitted an 8-K reporting other events and provided a corporate presentation as an exhibit. The filing lists written and soliciting communications under Rule 425 and Rule 14a-12, plus pre-commencement communications under Rules 14d-2(b) and 13e-4(c). The disclosure includes Exhibit 99.1, a corporate presentation dated August 29, 2025, and an Inline XBRL cover page. The document is signed by Frederick G. Vogt, Ph.D., J.D. in his capacity as Interim CEO, President, and General Counsel.
Iovance Biotherapeutics, Inc. filed an 8-K reporting written and soliciting communications under several securities rules and that it has engaged Jefferies to use commercially reasonable efforts to sell the company’s common shares from time to time under customary trading parameters. The filing references pre-commencement and solicitation rules and states the communication is dated August 22, 2025. The 8-K is signed by Frederick G. Vogt, Ph.D., J.D., Interim CEO and President, and General Counsel.
Iovance Biotherapeutics reported that Health Canada has approved its therapy Amtagvi (lifileucel) for patients with advanced melanoma who have already received anti-PD-1 and targeted therapies. This gives Canadian patients a new treatment option after other standard treatments have failed. The company shared this news through a press release, which is attached as an exhibit to the report.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) filed a Form 8-K announcing the recruitment of Corleen Roche as Chief Financial Officer, effective August 6, 2025.
The Executive Employment Agreement, signed July 7, 2025, replaces current Principal Financial Officer Matthew W. Rosinack. Roche will receive an annual base salary of $600,000, a $50,000 one-time sign-on bonus, and is eligible for an annual discretionary bonus up to 45 % of salary.
Equity incentives under the 2018 Equity Incentive Plan comprise (i) an option to purchase 300,000 shares at the closing price on the effective date, vesting one-third after 12 months and quarterly thereafter, and (ii) 150,000 restricted stock units with identical vesting cadence. Unvested awards forfeit upon termination except where severance conditions are met.
Severance terms for a termination without cause include: (1) salary continuation for 12 months, (2) pro-rated bonus, (3) immediate vesting of unvested equity, and (4) continuation of applicable benefits. Enhanced protection applies upon a change-of-control event.
Professional background: Roche, 59, has served as CFO of CG Oncology (2024-present), Immunome (2021-2023), and Biogen U.S. (2019-2021), following senior finance roles at Sandoz and Wyeth. She began her career at PwC and holds a B.A. in Accountancy from Villanova University.
The Company issued a press release (Exhibit 99.1) on July 15, 2025 to publicly announce the appointment.